Skip to main content
. 2017 Jan 15;7(3):677–693. doi: 10.7150/thno.16357

Figure 7.

Figure 7

Therapeutic efficiency of conventional chemotherapy and systemic nano-miR-100 (PMMNCs-miR-100) delivery or their combination in three PDXs. (A, C, and E) Tumor volume (mm3) measured in different treatment groups over time in FGFR3-amplified PDX HN-04-002 (A), FGFR3-amplified PDX HN-04-020 (C), and non-FGFR3-amplified PDX HN-03-09 (E). Dose schedules in different treatment groups are illustrated. IV, intravenously injection; IP, intraperitoneal injection; QW, once a week; BIW, twice a week. (B, D, and F) Body weight change of mice receiving different treatments over time in FGFR3-amplified PDX HN-04-002 (B), FGFR3-amplified PDX HN-04-020 (D), and non-FGFR3-amplified PDX HN-03-09 (F). Vehicle, phosphate buffer saline (PBS). All error bars indicate standard deviation.